Amylyx’s GLP-1 blocker avexitide cuts post-bariatric hypoglycemia event rate 55% in Phase 3
LUCIDITY met its FDA-agreed primary endpoint with a 55% lower composite rate of Level 2 and Level 3 hypoglycemic events, supporting an NDA planned by year-end.
